8-K: iCoreConnect Secures New Financing Through Convertible Note and Equity Line
Financing Agreement
iCoreConnect Inc. has entered into a new financing agreement involving a convertible note and an equity line of credit, alongside a warrant waiver from existing investors.
Summary
- iCoreConnect Inc. has issued a new convertible promissory note with a principal amount of $[GROSS], with $[NET] as the actual purchase price, and an original issue discount of $[OID].
- The note carries a one-time interest charge of 10%, equivalent to $[OID], and matures in twelve months from the issue date of December 5, 2024.
- The note can be converted into common stock at a price equal to 120% of the Nasdaq official closing price on the issue date, subject to adjustments.
- The conversion price can be reduced to the market price (90% of the lowest VWAP during the five trading days prior to conversion) if the company fails to make amortization payments or if certain Nasdaq listing deficiencies occur.
- The company has also entered into an equity purchase agreement with Crom Structured Opportunities Fund I, LP, committing to sell up to $20 million of common stock over 24 months.
- The company has agreed to file a registration statement within 90 days covering the resale of the shares underlying the convertible note and to have it declared effective within 120 days.
- The company has also agreed to file a registration statement within 30 days covering the shares issuable under the equity purchase agreement.
- The company has also obtained a waiver of anti-dilution provisions from certain warrant holders related to issuances made under the Strata Purchase Agreement.
Sentiment
Score: 5
Explanation: The document indicates a mixed sentiment. While the company has secured new financing, the terms of the convertible note and the equity line of credit suggest potential challenges and risks. The need for shareholder approval and the potential for dilution also contribute to a neutral to slightly negative sentiment.
Positives
- The company has secured additional funding through a convertible note and an equity line of credit.
- The conversion price of the note can be adjusted to a lower market price under certain circumstances, which could be beneficial for the note holder.
- The equity line of credit provides flexibility for the company to raise capital as needed.
- The company has obtained a waiver of anti-dilution provisions from certain warrant holders, which simplifies the capital structure.
Negatives
- The convertible note includes a 10% original issue discount, which reduces the net proceeds received by the company.
- The conversion price of the note is initially set at a premium of 120% of the market price, which may limit the conversion potential.
- The company is subject to certain restrictions and covenants under the note, which may limit its operational flexibility.
- The equity line of credit is subject to certain limitations and conditions, and the company may not be able to fully utilize it.
Risks
- The company may face challenges in meeting the amortization payments on the convertible note.
- The company may not be able to obtain shareholder approval for the issuance of shares exceeding the Exchange Cap.
- The company may face difficulties in maintaining the listing of its common stock on the Nasdaq Capital Market.
- The company may be unable to meet the deadlines for filing and effectiveness of the registration statements.
- The company may be subject to penalties and defaults if it fails to comply with the terms of the note or the equity purchase agreement.
Future Outlook
The company expects that any proceeds received from the equity line of credit will be used for working capital and general corporate purposes. The company is also required to file registration statements for the resale of shares underlying the convertible note and the equity purchase agreement.
Industry Context
This announcement reflects a trend of small-cap companies seeking alternative financing methods, such as convertible notes and equity lines, to fund their operations and growth. The inclusion of a warrant waiver suggests a desire to streamline the capital structure and potentially reduce future dilution.
Comparison to Industry Standards
- The use of convertible notes with adjustable conversion prices is a common practice in small-cap financing, allowing investors to benefit from potential upside while providing downside protection.
- The equity line of credit is a flexible financing tool that allows the company to raise capital as needed, but it also carries the risk of dilution for existing shareholders.
- The 10% original issue discount on the convertible note is within the typical range for such financings, but it does reduce the net proceeds received by the company.
- The requirement to file registration statements for the resale of shares is a standard practice to ensure compliance with securities laws and provide liquidity for investors.
- The waiver of anti-dilution provisions in existing warrants is a common practice to simplify the capital structure and facilitate new financings. Comparable companies such as Xometry and Desktop Metal have used similar financing methods.
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new shares under the equity line of credit and the conversion of the note.
- Existing warrant holders have waived anti-dilution provisions, which may impact their potential returns.
- Creditors may be impacted by the company's increased debt obligations.
- Employees may be impacted by the company's financial performance and ability to continue operations.
Next Steps
- The company needs to file registration statements for the resale of shares underlying the convertible note and the equity purchase agreement.
- The company needs to obtain shareholder approval for the issuance of shares exceeding the Exchange Cap.
- The company needs to monitor its compliance with the terms of the note and the equity purchase agreement.
- The company needs to manage its cash flow to meet the amortization payments on the convertible note.
Key Dates
| Date | Description |
|---|---|
| February 26, 2024 | Initial closing of the February 2024 offering. |
| April 26, 2024 | Amendment to the February 2024 offering. |
| May 31, 2024 | Special stockholder meeting to approve the issuance of common stock underlying the February 2024 Notes. |
| July 31, 2024 | Second closing of the February 2024 offering. |
| August 16, 2024 | Date of the Strata Purchase Agreement between the Company and Clearthink Capital Partners, LLC. |
| September 1, 2024 | Date after which the Holder is unable to obtain a standard 144 legal opinion letter. |
| September 30, 2024 | Date of the last financial statements mentioned in the document. |
| December 5, 2024 | Issue date of the new convertible note, equity purchase agreement, and registration rights agreements. |
| December 6, 2024 | Third closing of the February 2024 offering. |
Keywords
convertible note, equity line, registration rights, common stock, financing, warrant waiver, amortization payments, conversion price, dilution, Nasdaq
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.